aprevo® Lumbar Bi-lateral Posterior System
Personalized devices for posterior lumbar interbody fusion procedures
Device · OtherCompany source
Company profile
About Carlsmed
Carlsmed, Inc. is a publicly traded medical technology company pioneering AI-enabled personalized spine surgery solutions. The company's mission is to improve outcomes and decrease the cost of healthcare for spine surgery through its aprevo® personalized surgery platform, designed to improve the standard of care one patient at a time. The aprevo® platform is a fully integrated, end-to-end system for personalized spinal care that combines AI-enabled 3D surgical planning, precision alignment, and optimized fit. Each device is tailored to the individual patient's anatomy using CT scan data to create precise 3D models. The platform supports a broad spectrum of surgical techniques for both lumbar (anterior, posterior, and lateral) and cervical approaches, including ACDF, ALIF, LLIF, and TLIF procedures. Carlsmed's technology leverages AI-driven segmentation and prior outcomes data to develop personalized surgical plans and devices. The myaprevo® app provides surgeons and OR staff with intuitive 3D visualization tools for precise execution. Post-operatively, the platform analyzes surgical data to enhance reproducibility and improve future outcomes. Clinical evidence from over 500 patients demonstrates improved alignment predictability, reduced subsidence rates, and lower revision rates compared to standard implants. The company is headquartered in Carlsbad, California, and trades on NASDAQ under the ticker symbol CARL.
Company description Carlsmed official website
Primary marketSurgical AI & Robotics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Carlsmed?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- adult spinal deformity
- cervical spine conditions requiring fusion
- degenerative lumbar disease
Who it serves
- Health Systems
- Hospitals
- Spine Surgeons
Deployment & integration
Cloud Saas · Hybrid · Other deployment with recorded integration context.
Geographic context
MarketsUnited States
Company sourceOfficial website
Company milestones
Platform expansion
Q1 2026 revenue of $16.1 million (58% YoY growth), raised full year 2026 guidance to $72-77 million, completed enrollment of 300+ patient COMPASS Registry in Q4 2024
Partnerships
Recorded partners
No partners are currently listed.
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
aprevo® Personalized Interbody Devices
Patient-specific 3D-printed interbody implants for lumbar and cervical fusion
Device · OtherCompany source
aprevo® Technology Platform
AI-enabled end-to-end platform for personalized spine surgery planning and execution
Platform · HybridCompany source
corra™ Cervical Plating System
Patient-specific cervical fixation plates for personalized spine surgery
Device · OtherCompany source
myaprevo®
3D visualization app for surgeons and OR staff during personalized spine procedures
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Personalized Spine Surgery in Adult Deformity: Reoperation Rates and Mechanical Complications Following Customized Planning and Interbody Implant Use.Global spine journal · Dec 20, 2025
Analysis of Personalized Interbody Implants in the Surgical Treatment of Adult Spinal Deformity.Global spine journal · Mar 1, 2025
Tomographic Assessment of Fusion Rate, Implant-Endplate Contact Area, Subsidence, and Alignment With Lumbar Personalized Interbody Implants at 1-Year Follow-Up.International journal of spine surgery · Aug 30, 2024
Mismatch Between Pelvic Incidence and Lumbar Lordosis After Personalized Interbody Fusion: The Importance of Preoperative Planning and Alignment in Degenerative Spine Diseases.International journal of spine surgery · Aug 30, 2024
Changes in Alignment at Untreated Vertebral Levels Following Short-Segment Fusion Using Personalized Interbody Cages: Leveraging Personalized Medicine to Reduce the Risk of Reoperation.International journal of spine surgery · Aug 30, 2024
Predictability in Achieving Target Intervertebral Lordosis Using Personalized Interbody Implants.International journal of spine surgery · Aug 30, 2024
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
aprevo® Digital SegmentationK231955 · 510k · Nov 3, 2023
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
82% achieved targeted intervertebral alignment within 5°
Predictable alignment in personalized interbody procedures
94% average device to vertebral endplate contact at 1-year
Improved graft contact on CT follow-up
96% of levels with zero subsidence at 1-year
Subsidence mitigation on CT follow-up
44% increase in alignment restoration
Preoperatively malaligned degenerative patients
45% improvement in achieving targeted PI-LL within 5°
Complex adult deformity vs stock implants
<2% revision rate for mechanical complications
Adult spinal deformity patients in COMPASS Registry
28% decrease in posterior rod stress
Biomechanical studies of endplate matched implants
50x increase in contact area
Biomechanical comparison to standard implants
30% reduction in stress concentration on endplate
Biomechanical performance
Adult spinal deformity study
Complex adult deformity correction with personalized implants
45% improvement in achieving targeted PI-LL within 5º compared to stock implants
COMPASS™ Registry (Multi-center study)
Adult spinal deformity treatment with personalized interbody devices
<2% rate of revision surgery for mechanical complications in adult spinal deformity patients
Multi-center clinical study
Improved graft contact and subsidence mitigation in spine fusion
94% average device to vertebral endplate contact at 1-year follow-up and 96% of levels with zero subsidence
Multi-center clinical study (500+ patients)
Predictable intervertebral alignment in spine fusion procedures
82% of personalized aprevo® interbody levels achieved targeted alignment within 5°
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Mike Cordonnier
Chairman and Chief Executive Officer
Jennifer Kamocsay
Chief Legal Officer and Secretary
06 · Company updates
Updates from Carlsmed
Recent articles published on Carlsmed's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Surgical AI & Robotics
Companies developing surgical technologies enhanced by AI, including robotic surgical systems, AI-powered surgical assistance and navigation tools, autonomous surgical robotics, and surgical data and analytics platforms. Covers both the performance of surgery and the analysis of surgical outcomes and OR efficiency.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.